Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Gleevec Decreases Cancer Recurrence for Patients with a Type of Gastrointestinal Cancer
May 1st, 2007
Kettering Cancer Center's Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec (R)) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib. For more information about this National Cancer Institute funded study, go to: www.cancer.gov/newscenter/pressreleases/GISTtrial Keywords: Cancer, Drugs, Gastroenterology, Gleevec, Imatinib Mesylate, Oncology, Pharmaceuticals,...
Source: Cancer Weekly (2007-05-01)
|
